255 related articles for article (PubMed ID: 24992974)
21. Cancer Implications for Patients with Endometriosis.
Wilbur MA; Shih IM; Segars JH; Fader AN
Semin Reprod Med; 2017 Jan; 35(1):110-116. PubMed ID: 28049216
[TBL] [Abstract][Full Text] [Related]
22. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
23. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
24. Endometriosis-associated Ovarian Cancers.
Anglesio MS; Yong PJ
Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
[TBL] [Abstract][Full Text] [Related]
25. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
27. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
[TBL] [Abstract][Full Text] [Related]
28. Histologic transformation of benign endometriosis to early epithelial ovarian cancer.
Sainz de la Cuesta R; Eichhorn JH; Rice LW; Fuller AF; Nikrui N; Goff BA
Gynecol Oncol; 1996 Feb; 60(2):238-44. PubMed ID: 8631545
[TBL] [Abstract][Full Text] [Related]
29. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
30. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
Gadducci A; Lanfredini N; Tana R
Gynecol Endocrinol; 2014 Sep; 30(9):612-7. PubMed ID: 24905724
[TBL] [Abstract][Full Text] [Related]
31. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract][Full Text] [Related]
33. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability.
Amemiya S; Sekizawa A; Otsuka J; Tachikawa T; Saito H; Okai T
Int J Gynaecol Obstet; 2004 Sep; 86(3):371-6. PubMed ID: 15325855
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Kurman RJ; Shih IeM
Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
[TBL] [Abstract][Full Text] [Related]
35. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation.
Wells M
Int J Gynecol Pathol; 2004 Oct; 23(4):316-20. PubMed ID: 15381900
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer.
Kumari P; Sharma I; Saha SC; Srinivasan R; Minhas P
J Cancer Res Ther; 2021; 17(4):1003-1011. PubMed ID: 34528556
[TBL] [Abstract][Full Text] [Related]
38. Analysis of p53 and c-erbB-2 expression in ovarian endometrioid carcinomas arising in endometriosis.
Prefumo F; Venturini PL; Fulcheri E
Int J Gynecol Pathol; 2003 Jan; 22(1):83-8. PubMed ID: 12496703
[TBL] [Abstract][Full Text] [Related]
39. Endometrial, Ovarian, and Peritoneal Involvement by Endometrioid Carcinoma, Yolk Sac Tumor, and Endometriosis: Molecular Evidence for a Shared Precursor.
Halling GC; Udager AM; Skala SL
Int J Gynecol Pathol; 2023 May; 42(3):247-253. PubMed ID: 35639393
[TBL] [Abstract][Full Text] [Related]
40. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
Mansor S; McCluggage WG
Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
